Efficacy and Safety of Decitabine-Based Myeloablative Preconditioning Regimen for allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.02.037
- Author:
Xia-Wei ZHANG
1
;
Jing-Jing YANG
1
;
Ning LE
1
;
Yu-Jun WEI
1
;
Ya-Nan WEN
1
;
Nan WANG
1
;
Yi-Fan JIAO
1
;
Song-Hua LUAN
2
;
Li-Ping DOU
2
;
Chun-Ji GAO
2
Author Information
1. Medical School of Chinese PLA, Beijing 100853, China.
2. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- Keywords:
decitabine;
transplantation conditioning regimen;
acute myeloid leukemia
- MeSH:
Humans;
Leukemia, Myeloid, Acute/therapy*;
Hematopoietic Stem Cell Transplantation/methods*;
Decitabine/therapeutic use*;
Transplantation Conditioning/methods*;
Retrospective Studies;
Graft vs Host Disease;
Transplantation, Homologous;
Male;
Female;
Adult;
Middle Aged;
Adolescent;
Young Adult
- From:
Journal of Experimental Hematology
2025;33(2):557-564
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the efficacy and safety of decitabine-based myeloablative preconditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML).
METHODS:The clinical characteristics and efficacy of 115 AML patients who underwent allo-HSCT at the First Medical Center of Chinese PLA General Hospital from August 2018 to August 2022 were retrospectively analyzed, including 37 patients treated with decitabine conditioning regimen (decitabine group) and 78 patients without decitabine conditioning regimen (non-decitabine group). The cumulative incidence of relapse (CIR), overall survival (OS), leukemia-free survival (LFS), non-relapse mortality (NRM) and graft versus host disease (GVHD) were analyzed.
RESULTS:For the patients in first complete remission (CR1) state before allo-HSCT, the 1-year relapse rates of decitabine group(22 cases) and non-decitabine group(69 cases) were 9.1% and 29.6%, respectively, the difference was statistically significant(P =0.042). The 1-year cumulative incidence of acute graft-versus-host disease (aGVHD) in decitabine group and non-decitabine group was 62.2% and 70.5%, respectively, and the 1-year cumulative incidence of chronic inhibitor-versus-host disease (cGVHD) was 18.9% and 14.1%, respectively, there were no significant differences in the incidence of aGVHD and cGVHD between the two groups (P >0.05). Of the 115 patients, there were no significantly differences in the 1-year CIR(21.7% vs 28.8%, P =0.866), NRM(10.9% vs 3.9%, P =0.203), OS(75.2% vs 83.8%, P =0.131) and LFS(74.6% vs 69.1%, P =0.912) between the decitabine group(37 cases) and the non-decitabine group(78 cases).
CONCLUSION:Decitabine-based conditioning regimen could reduce the relapse rate of AML CR1 patients with good safety.
